FB-Plus, FB-Plus clinical trials

A two-part study: open label, dose escalation phase aimed to evaluate the safety and tolerability of two different doses of allogeneic fibroblasts for the treatment of chronic refractory wounds and identifying the best dose for subsequent cohort expansion phase aimed to assess efficacy and confirm safety and tolerability

This study is looking into a new treatment for chronic wounds that haven't healed with other methods. It's testing if a cell treatment called FB-Plus is safe and helps wounds heal, starting with finding the best dose and then checking how well it works.